PMID- 24915072 OWN - NLM STAT- MEDLINE DCOM- 20150330 LR - 20171116 IS - 1873-7064 (Electronic) IS - 0028-3908 (Linking) VI - 85 DP - 2014 Oct TI - Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study. PG - 284-9 LID - S0028-3908(14)00195-6 [pii] LID - 10.1016/j.neuropharm.2014.05.028 [doi] AB - Rotigotine (RTG) is a non-ergot dopamine agonist developed as a new transdermal formulation, indicated for use in early and advanced Parkinson's disease (PD). The potential advantages of the RTG patch include immediacy of effect onset, constant drug delivery, better tolerability avoiding drug peaks and easy of use, helping patient's compliance. So, RTG patch appears to be a suitable candidate in the treatment of patients with atypical parkinsonism. The present is an observational study to evaluate the efficacy and tolerability of RTG in patients affected by atypical parkinsonian disorders. 61 subjects with diagnosis of atypical parkinsonian disorders were treated with transdermal RTG. Diagnosis was: Parkinson disease with dementia, multiple system atrophy parkinsonian type, multiple system atrophy cerebellar type, progressive sopranuclear palsy, cortico-basal degeneration, Lewy body dementia and fronto-temporal dementia with parkinsonism. Patients were evaluated by UPDRS-III, NPI, MMSE and adverse events (AEs) were recorded. Patients treated with RTG show an overall decrease of UPDRS III scores without increasing behavioral disturbances. Main adverse events (AE) were hypotension (14 patients), nausea (13), vomiting (5), drowsiness (5), tachycardia (2) dystonia (3 patients, all treated with concomitant l-dopa). On the whole, 16 patients were affected by AE and 7 patients suspended RTG treatment due to AE (vomiting, tachycardia and sleepiness). In our population transdermal RTG seems to be effective and well tolerated. Due to its system of drug delivery, RTG appears to be a suitable therapy in elderly patients as it has a good tolerability profile, improves patient's compliance and helps management of fragile patients. CI - Copyright (c) 2014 Elsevier Ltd. All rights reserved. FAU - Moretti, D V AU - Moretti DV AD - IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy. Electronic address: davide.moretti@afar.it. FAU - Binetti, G AU - Binetti G AD - IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy. FAU - Zanetti, O AU - Zanetti O AD - IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy. FAU - Frisoni, G B AU - Frisoni GB AD - IRCCS S. Giovanni di Dio Fatebenefratelli, Brescia, Italy. LA - eng PT - Clinical Trial PT - Journal Article PT - Observational Study DEP - 20140607 PL - England TA - Neuropharmacology JT - Neuropharmacology JID - 0236217 RN - 0 (Antiparkinson Agents) RN - 0 (Dopamine Agonists) RN - 0 (Tetrahydronaphthalenes) RN - 0 (Thiophenes) RN - 87T4T8BO2E (rotigotine) SB - IM MH - Administration, Cutaneous MH - Aged MH - Antiparkinson Agents/*administration & dosage/adverse effects MH - Dopamine Agonists/*administration & dosage/adverse effects MH - Follow-Up Studies MH - Humans MH - Parkinsonian Disorders/*drug therapy MH - Psychiatric Status Rating Scales MH - Severity of Illness Index MH - Tetrahydronaphthalenes/*administration & dosage/adverse effects MH - Thiophenes/*administration & dosage/adverse effects MH - Transdermal Patch/adverse effects MH - Treatment Outcome OTO - NOTNLM OT - Atypical parkinsonism syndrome OT - Observational study OT - Therapy OT - Transdermal rotigotine EDAT- 2014/06/11 06:00 MHDA- 2015/03/31 06:00 CRDT- 2014/06/11 06:00 PHST- 2014/03/01 00:00 [received] PHST- 2014/05/15 00:00 [revised] PHST- 2014/05/16 00:00 [accepted] PHST- 2014/06/11 06:00 [entrez] PHST- 2014/06/11 06:00 [pubmed] PHST- 2015/03/31 06:00 [medline] AID - S0028-3908(14)00195-6 [pii] AID - 10.1016/j.neuropharm.2014.05.028 [doi] PST - ppublish SO - Neuropharmacology. 2014 Oct;85:284-9. doi: 10.1016/j.neuropharm.2014.05.028. Epub 2014 Jun 7.